Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dengvaxia
- Development stage
- Approved
- Lead developer
- Parent
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Dengvaxia (CYD-TDV) is a live, attenuated tetravalent vaccine developed by Sanofi Pasteur for the prevention of dengue disease caused by all four dengue virus serotypes (1, 2, 3, and 4). It is a chimeric vaccine engineered using recombinant DNA technology, where the PrM (pre-membrane) and E (envelope) structural genes of the yellow fever attenuated 17D strain vaccine are replaced with those from the four dengue serotypes. The vaccine is administered subcutaneously. While approved in several regions, its use is generally restricted to individuals with a confirmed prior dengue infection due to an increased risk of severe dengue in those who have not been previously infected, a phenomenon known as antibody-dependent enhancement (ADE).
- Brand names
- Dengvaxia
- Other names
- live, attenuated dengue serotype 1, 2, 3, and 4 viruschimeric yellow fever dengue-tetravalent dengue vaccineDengue Tetravalent Vaccine, LiveDengue vaccine recombinant tetravalentDengue virus vaccine
02
Targets
DENV-1 antigens (Dengue virus serotype 1 antigens)Dengue virus serotype 2 premembrane and envelope proteins (prM/E)DENV-3 E (Dengue virus serotype 3 envelope protein)Dengue virus serotype 4 premembrane and envelope proteins
Beyond the preview
Go deeper on Dengvaxia.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dengvaxia.